Clarifying the critical differences between the enzymatic stromal vascular fraction and the mechanically derived stromal vascular tissue or nanofat for spinal cord injury applications.
Nonnarath C., Serratrice N.
Animal Study on Spinal Cord Injury, published in Stem Cell Res Ther (2026) — summary generated from the PubMed abstract.
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Animal Study
- Journal
- Stem Cell Res Ther (2026)
- Country
- England
- Reported sample size
- —
- PMID
- 41964032
- DOI
- 10.1186/s13287-026-04956-z
Abstract (original English)
This letter aims to address the increasing confusion surrounding the concepts and terminology of enzymatically derived stromal vascular fraction (eSVF) and mechanically processed adipose tissue, which is often referred to as stromal vascular tissue (mSVT) or nanofat. Although these products are often presented as equivalent, they differ fundamentally in their biological composition, processing methods and regulatory classification. Enzymatic digestion yields a homogeneous, adipocyte-free cellular suspension, whereas mechanical processing preserves adipocytes, extracellular matrix fragments and tissue architecture. In the context of spinal cord injury, these differences give rise to biologically plausible concerns and procedural constraints, particularly with regard to intramedullary delivery. This work highlights the importance of precise terminology, transparent reporting of methods, and careful regulatory alignment to ensure the safe and scientifically sound translation of clinical applications.
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
- • This is preclinical work; animal or laboratory results cannot be applied to humans.
Evidence level
Evidence comes from animal or laboratory studies and has not been confirmed in humans.
How we grade evidenceRelated research
- Level ASystematic Review
Host immune determinants of stromal vascular fraction graft survival: Toward a concept of SVF therapy resistance - A systematic narrative review.
Systematic Review on Spinal Cord Injury, Chronic Inflammation, Immune Modulation, published in Cell Transplant (2026) — summary generated from the PubMed abstract.
- 2026
Cell Transplant - Level ASystematic Review
Stem cell-derived exosome treatment for acute spinal cord injury: a systematic review and meta-analysis based on preclinical evidence.
Systematic Review on Spinal Cord Injury, published in Front Neurol (2025) — summary generated from the PubMed abstract.
- 2025
Front Neurol - Level ASystematic Review
Brain-derived neurotrophic factor (BDNF) as biomarker in stem cell-based therapies of preclinical spinal cord injury models: A systematic review.
Systematic Review on Spinal Cord Injury, published in Tissue Cell (2025) — summary generated from the PubMed abstract.
- 2025
Tissue Cell - Level ASystematic Review
Stem cell-derived exosomes for traumatic spinal cord injury: a systematic review and network meta-analysis based on a rat model.
Systematic Review on Spinal Cord Injury, published in Cytotherapy (2024) — summary generated from the PubMed abstract.
- 2024
Cytotherapy - Level ASystematic Review
Mesenchymal Stem Cells for the Treatment of Spinal Cord Injury in Rat Models: A Systematic Review and Network Meta-Analysis.
Systematic Review on Spinal Cord Injury, published in Cell Transplant (2024) — summary generated from the PubMed abstract.
- 2024
Cell Transplant - Level ASystematic Review
Mesenchymal stem cell-derived extracellular vesicles therapy in traumatic central nervous system diseases: a systematic review and meta-analysis.
Systematic Review with a reported sample of 52 on Spinal Cord Injury, published in Neural Regen Res (2023) — summary generated from the PubMed abstract.
- 2023
- n = 52
Neural Regen Res